Market Cap 194.54M
Revenue (ttm) 49.22M
Net Income (ttm) -36.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -74.69%
Debt to Equity Ratio 0.76
Volume 65,000
Avg Vol 164,490
Day's Range N/A - N/A
Shares Out 55.58M
Stochastic %K 82%
Beta 3.10
Analysts Strong Sell
Price Target $5.60

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 81 69 16 00
Address:
8, rue de la Croix Jarry, Paris, France
mikefbi
mikefbi Oct. 2 at 9:25 PM
$CLLS up up away
0 · Reply
BOUDIN420
BOUDIN420 Oct. 1 at 9:04 PM
0 · Reply
rlkloehn
rlkloehn Oct. 1 at 6:08 PM
$CLLS Dr. David Sourdive, co-founder and EVP of Cellectis, recently shared revolutionary information on next-generation CAR-T cells at a conference. As a pioneer of genomic editing, Cellectis is revolutionizing cancer therapies. This marks a new era in medicine, where cells become a field of innovation for engineers. The potential? More effective and less invasive treatments for cancer patients worldwide. Curious to know the future of cell therapies: • How do cells turn into "living drones" within our body? • What makes these new CAR-T cells "intelligent" and how could they revolutionize cancer treatment? • How could ready-to-use cell cancer drugs change the landscape of personalized medicine? Watch Dr. Sourdive's full presentation to learn more about this breakthrough technology! http://go.3ds.com/N2eT
0 · Reply
Rick_Reyn8lds
Rick_Reyn8lds Oct. 1 at 3:36 PM
$CLLS NXXT execution cadence matters 02 2025 at 5.09M then 07 at 8 plus and 08 at 7.51M while YTD 51.6M suggests 70 to 80M 2025 feasible at current pace price to sales compresses on growth PT 5 to 6 window opening 🧠
0 · Reply
highnihilism
highnihilism Oct. 1 at 9:34 AM
$AMC Networks Trade Count: 23 | Total $: 3.6 K | 0.14 × 90-Day Avg $: 25.7 K | Call $: 3 K | Put $: 630 | % Single-Leg: 87% | % Multi-Leg: 11% | % Contingent: 3% $NRIX Nurix Therapeutics Trade Count: 15 | Total $: 3.2 K | 0.23 × 90-Day Avg $: 14.2 K | Call $: 3 K | Put $: 235 | % Single-Leg: 87% | % Multi-Leg: 0% | % Contingent: 13% $CLLS Cellectis Trade Count: 6 | Total $: 3 K | 0.66 × 90-Day Avg $: 4.6 K | Call $: 3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $VB Vanguard Small-Cap ETF Trade Count: 14 | Total $: 21.3 K | 0.60 × 90-Day Avg $: 35.6 K | Call $: 3 K | Put $: 18.3 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
BOUDIN420
BOUDIN420 Sep. 29 at 7:09 PM
0 · Reply
YouVSYou
YouVSYou Sep. 29 at 5:37 PM
$CLLS interesting dip
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 7:54 AM
$CLLS Excellent article that nails exactly where CLLS stands right now. So if you want to update your CLLS knowledge or get acquainted with CLLS, this is a must read. https://beyondspx.com/quote/CLLS/analysis/cellectis-charts-a-new-course-allogeneic-car-t-prowess-and-strategic-alliances-drive-future-growth-clls
0 · Reply
rlkloehn
rlkloehn Sep. 26 at 7:56 PM
$CLLS Factor Bioscience filed a complaint in the United States against Cellectis and AstraZeneca for patent counterfeiting related to gene editing technologies (mRNA + TALEN) used in cancer therapies. Reuters According to the complaint, Cellectis allegedly copied Factor's technology, and AstraZeneca, which entered into a license/collaboration agreement with Cellectis in 2023, would also be responsible for the use of this technology.
0 · Reply
rlkloehn
rlkloehn Sep. 24 at 3:01 AM
$CLLS https://www.linkedin.com/posts/cellectis_in-a-few-days-well-open-the-doors-of-our-activity-7376266902031056896-CeZA
0 · Reply
Latest News on CLLS
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 11:50 AM EDT - 2 months ago

Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript


Cellectis Reports Financial Results for the First Quarter 2025

May 12, 2025, 4:30 PM EDT - 5 months ago

Cellectis Reports Financial Results for the First Quarter 2025


Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

Mar 14, 2025, 10:36 AM EDT - 7 months ago

Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript


Cellectis: Poised To Start Answering Questions In 2025

Dec 12, 2024, 3:08 PM EST - 10 months ago

Cellectis: Poised To Start Answering Questions In 2025


Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 1:59 PM EST - 11 months ago

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript


Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

May 30, 2024, 2:06 PM EDT - 1 year ago

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript


Cellectis Reports Financial Results for First Quarter 2024

May 28, 2024, 4:30 PM EDT - 1 year ago

Cellectis Reports Financial Results for First Quarter 2024


Cellectis' Shareholders Meeting to be Held on December 22, 2023

Nov 17, 2023, 4:30 PM EST - 2 years ago

Cellectis' Shareholders Meeting to be Held on December 22, 2023


Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 2:22 PM EST - 2 years ago

Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript


Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects

Nov 3, 2023, 6:57 PM EDT - 2 years ago

Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects


mikefbi
mikefbi Oct. 2 at 9:25 PM
$CLLS up up away
0 · Reply
BOUDIN420
BOUDIN420 Oct. 1 at 9:04 PM
0 · Reply
rlkloehn
rlkloehn Oct. 1 at 6:08 PM
$CLLS Dr. David Sourdive, co-founder and EVP of Cellectis, recently shared revolutionary information on next-generation CAR-T cells at a conference. As a pioneer of genomic editing, Cellectis is revolutionizing cancer therapies. This marks a new era in medicine, where cells become a field of innovation for engineers. The potential? More effective and less invasive treatments for cancer patients worldwide. Curious to know the future of cell therapies: • How do cells turn into "living drones" within our body? • What makes these new CAR-T cells "intelligent" and how could they revolutionize cancer treatment? • How could ready-to-use cell cancer drugs change the landscape of personalized medicine? Watch Dr. Sourdive's full presentation to learn more about this breakthrough technology! http://go.3ds.com/N2eT
0 · Reply
Rick_Reyn8lds
Rick_Reyn8lds Oct. 1 at 3:36 PM
$CLLS NXXT execution cadence matters 02 2025 at 5.09M then 07 at 8 plus and 08 at 7.51M while YTD 51.6M suggests 70 to 80M 2025 feasible at current pace price to sales compresses on growth PT 5 to 6 window opening 🧠
0 · Reply
highnihilism
highnihilism Oct. 1 at 9:34 AM
$AMC Networks Trade Count: 23 | Total $: 3.6 K | 0.14 × 90-Day Avg $: 25.7 K | Call $: 3 K | Put $: 630 | % Single-Leg: 87% | % Multi-Leg: 11% | % Contingent: 3% $NRIX Nurix Therapeutics Trade Count: 15 | Total $: 3.2 K | 0.23 × 90-Day Avg $: 14.2 K | Call $: 3 K | Put $: 235 | % Single-Leg: 87% | % Multi-Leg: 0% | % Contingent: 13% $CLLS Cellectis Trade Count: 6 | Total $: 3 K | 0.66 × 90-Day Avg $: 4.6 K | Call $: 3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $VB Vanguard Small-Cap ETF Trade Count: 14 | Total $: 21.3 K | 0.60 × 90-Day Avg $: 35.6 K | Call $: 3 K | Put $: 18.3 K | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
BOUDIN420
BOUDIN420 Sep. 29 at 7:09 PM
0 · Reply
YouVSYou
YouVSYou Sep. 29 at 5:37 PM
$CLLS interesting dip
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 7:54 AM
$CLLS Excellent article that nails exactly where CLLS stands right now. So if you want to update your CLLS knowledge or get acquainted with CLLS, this is a must read. https://beyondspx.com/quote/CLLS/analysis/cellectis-charts-a-new-course-allogeneic-car-t-prowess-and-strategic-alliances-drive-future-growth-clls
0 · Reply
rlkloehn
rlkloehn Sep. 26 at 7:56 PM
$CLLS Factor Bioscience filed a complaint in the United States against Cellectis and AstraZeneca for patent counterfeiting related to gene editing technologies (mRNA + TALEN) used in cancer therapies. Reuters According to the complaint, Cellectis allegedly copied Factor's technology, and AstraZeneca, which entered into a license/collaboration agreement with Cellectis in 2023, would also be responsible for the use of this technology.
0 · Reply
rlkloehn
rlkloehn Sep. 24 at 3:01 AM
$CLLS https://www.linkedin.com/posts/cellectis_in-a-few-days-well-open-the-doors-of-our-activity-7376266902031056896-CeZA
0 · Reply
3DBuilds
3DBuilds Sep. 22 at 1:49 AM
0 · Reply
3DBuilds
3DBuilds Sep. 20 at 1:21 AM
0 · Reply
PharmaExpert
PharmaExpert Sep. 19 at 4:25 PM
$AKBA, $INDP, $VRCA, $AQST, $CLLS 🔥🔥🔥🔥🔥
0 · Reply
mikefbi
mikefbi Sep. 19 at 2:04 PM
$CLLS Up up away
0 · Reply
topstockalerts
topstockalerts Sep. 19 at 12:09 PM
$CLLS keep an eye on it for today
0 · Reply
Ezy_Money_083
Ezy_Money_083 Sep. 19 at 11:45 AM
@MS_Tammy $CLLS News?
0 · Reply
dbr_island
dbr_island Sep. 19 at 10:44 AM
$CLLS watching…. INVZ 🚨NEWS OUT🚨TUTES ARE LOADING👇 INVZ shouldn’t be under $2, 3, or $4 I’m telling you🎯 YOU IGNORE SMART MONEY YOU IGNORE BIG MONEY
0 · Reply
mikefbi
mikefbi Sep. 11 at 11:06 AM
$CLLS Green
0 · Reply
rlkloehn
rlkloehn Sep. 10 at 3:51 PM
$CLLS https://x.com/cellectis/status/1965760989535899968?t=JtXj-YDlU1GoTjuM1m-v9Q& s=19
0 · Reply
3DBuilds
3DBuilds Sep. 9 at 9:19 PM
0 · Reply
mikefbi
mikefbi Sep. 9 at 3:54 PM
0 · Reply
mikefbi
mikefbi Aug. 29 at 8:52 PM
$CLLS Still
0 · Reply